^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | RAF709 (BRAF inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Excerpt:
RAF709 dosed at 60 mg/kg or 200 mg/kg...daily led to tumor growth inhibition in a subset of NSCLC PDX tumors, in which tumors that harbor mutation of BRAF, NRAS, or KRAS were enriched among the better responders...These data further support that RAF709 demonstrates significant antitumor activity in tumors driven by either oncogenic BRAF or RAS.
DOI:
10.1158/0008-5472.CAN-17-2033
